Testosterone Enanthate in Adolescents (Ages 12 to 17): Developmental Impact

Who Receives Testosterone Enanthate Between Ages 12 and 17?

Testosterone enanthate is not routinely prescribed to teenagers. The drug has two well-supported pediatric indications: hypogonadotropic hypogonadism (a failure of the pituitary to signal the testes) and constitutional delay of growth and puberty (CDGP). Both conditions are confirmed with serum testosterone, LH, FSH, and bone age X-ray before any prescription is written.

The Endocrine Society's 2023 Clinical Practice Guideline on androgen therapy states that "testosterone therapy should not be initiated in adolescent males without a confirmed diagnosis of hypogonadism" and recommends against empirical treatment of low-normal testosterone in otherwise healthy teenagers. Prescribing outside these indications, whether for athletic performance, muscle gain, or perceived low energy, is medically unjustified and potentially harmful.

Constitutional Delay of Growth and Puberty (CDGP)

CDGP accounts for roughly 60 to 65% of delayed puberty cases in males referred to pediatric endocrinology [1]. Boys with CDGP have a normal hypothalamic-pituitary-gonadal (HPG) axis but a delayed biological clock. A short course of low-dose testosterone enanthate, typically 50 mg IM monthly for 3 to 6 months, can initiate secondary sexual development and improve psychological well-being without meaningfully compromising adult height.

A 2020 study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that boys with CDGP treated with 50 mg testosterone enanthate monthly for 6 months showed equivalent adult height outcomes compared to untreated controls, while reporting significantly better self-esteem scores at 12-month follow-up [2].

Primary and Secondary Hypogonadism

Primary hypogonadism (testicular failure, as in Klinefelter syndrome 47,XXY) and secondary hypogonadism (pituitary or hypothalamic disease) require longer-term testosterone replacement. Dosing typically follows a gradual induction: 50 mg/month for the first 6 months, titrated upward to adult replacement doses of 150 to 200 mg every 2 weeks over 2 to 3 years. This staged approach mimics the natural progression of puberty and reduces the risk of premature epiphyseal fusion [3].

How Testosterone Enanthate Affects Bone Development

Testosterone has a dual role in adolescent bone biology. It stimulates periosteal bone formation, increases cortical thickness, and drives the pubertal growth spurt. It also, via aromatization to estradiol, accelerates growth plate fusion. This dual action is the core developmental risk.

Growth Plate Closure and Adult Height

The epiphyseal growth plates, located at the ends of long bones, are responsible for longitudinal bone growth. They close in response to rising estradiol levels during puberty. Testosterone enanthate, when given at supraphysiologic doses, raises both testosterone and estradiol simultaneously, pushing growth plate closure faster than the natural timeline.

Data from a 2019 Cochrane review of androgen therapy in boys with short stature found that higher testosterone doses were associated with greater bone age advancement relative to chronological age advancement, a ratio that predicted shorter adult height in a subset of treated boys [4]. The review noted that doses exceeding 100 mg/month carried a higher risk of disproportionate bone age acceleration.

A 12-year longitudinal cohort study from the Netherlands, published in Clinical Endocrinology in 2018, found that boys treated with testosterone enanthate at doses above 125 mg/month during mid-puberty (Tanner stage 2 to 3) reached adult heights averaging 3.2 cm below their predicted height based on mid-parental height [5].

Bone Mineral Density: A Protective Effect at Physiologic Doses

Not all skeletal effects are negative. Boys with untreated hypogonadism accumulate lower bone mineral density (BMD) than age-matched peers, and testosterone replacement at physiologic doses corrects this deficit. A study in the Journal of Bone and Mineral Research (2021) showed that adolescent males with Klinefelter syndrome who received testosterone replacement therapy beginning at Tanner stage 2 had lumbar spine BMD Z-scores of 0.12 ± 0.8 at age 18, compared to -0.74 ± 1.1 in untreated age-matched Klinefelter controls [6].

The protective effect on BMD is dose-appropriate. Supraphysiologic dosing does not confer additional bone benefit and introduces the growth plate risks described above.

Impact on the Hypothalamic-Pituitary-Gonadal (HPG) Axis

Exogenous testosterone suppresses the HPG axis through negative feedback. In adolescents, whose HPG axis is still maturing, this suppression carries distinct risks compared to adults.

LH and FSH Suppression

Within 2 to 4 weeks of initiating testosterone enanthate at doses of 100 mg or higher, serum LH and FSH fall to castrate levels in most adolescents. This suppression is reversible after short-course CDGP treatment (3 to 6 months). Recovery of gonadotropin pulsatility typically occurs within 3 to 6 months after discontinuation [7].

In cases of prolonged use (greater than 12 months) or supraphysiologic dosing, HPG axis recovery may take 6 to 18 months. A small subset of adolescents may experience persistent hypogonadotropic hypogonadism after stopping, particularly if treatment began before HPG axis maturation was complete.

Spermatogenesis and Future Fertility

Spermatogenesis requires intratesticular testosterone concentrations that are orders of magnitude higher than serum levels. Exogenous testosterone lowers intratesticular testosterone by suppressing LH, which drives Leydig cell testosterone production locally. The result is impaired sperm production.

In a 2017 study published in Fertility and Sterility, adolescent males (ages 15 to 19) who used testosterone preparations, including enanthate, for more than 6 months showed azoospermia or severe oligospermia in 73% of cases at end-of-treatment [8]. Among those who discontinued, semen parameters recovered to baseline in approximately 80% within 12 months, though recovery was slower in those who had started treatment at younger ages.

For adolescents with primary hypogonadism who require long-term testosterone replacement, sperm banking before treatment initiation should be discussed, though testicular function in primary hypogonadism is already compromised.

Psychological and Neurological Development

Testosterone plays a documented role in adolescent brain development, influencing limbic system maturation, amygdala reactivity, and risk-taking behavior. Supraphysiologic doses amplify these effects.

Mood, Aggression, and Behavioral Effects

The relationship between exogenous testosterone and mood in adolescents is not linear. At physiologic replacement doses in hypogonadal boys, testosterone therapy consistently improves mood, reduces depressive symptoms, and increases energy. A 2022 meta-analysis in JAMA Pediatrics (covering 14 controlled studies, N=612 adolescent males with hypogonadism) found a standardized mean difference of -0.48 on validated depression scales after 6 to 12 months of physiologic testosterone replacement [9].

At supraphysiologic doses, the picture changes. Elevated testosterone and its metabolites increase amygdala reactivity to social threat cues, reduce prefrontal inhibitory control over limbic responses, and may increase impulsive aggression. These neurological changes are of particular concern in adolescents because the prefrontal cortex is not fully myelinated until approximately age 25.

Cognitive and Academic Function

There is limited high-quality evidence linking physiologic testosterone replacement to negative academic outcomes. One prospective observational study from Sweden (2020, N=88) found no significant difference in school performance between hypogonadal adolescents treated with testosterone enanthate and age-matched healthy controls over a 3-year period [10].

Illicit supraphysiologic use is a separate matter. A 2019 systematic review in Drug and Alcohol Dependence identified associations between anabolic-androgenic steroid use in adolescents and increased risk of depression, mania, and substance use disorders in early adulthood, though study heterogeneity limits definitive causal conclusions [11].

Cardiovascular and Metabolic Effects

Lipid Profile Changes

Testosterone enanthate at typical replacement doses (50 to 100 mg/month) produces modest changes in lipid profiles in adolescents. HDL cholesterol decreases by approximately 10 to 15% and LDL may rise slightly. These changes are generally reversible after discontinuation.

At higher doses, HDL suppression is more pronounced. A study of adolescent male anabolic steroid users (mean age 16.2 years, mean weekly dose equivalent to 300 mg testosterone enanthate) found mean HDL levels of 28 mg/dL, compared to 52 mg/dL in age-matched controls [12]. Whether these adolescent-onset lipid changes translate to accelerated atherosclerosis in adulthood remains an active area of investigation.

Hematologic Effects

Testosterone stimulates erythropoiesis. Supraphysiologic doses in adolescents can raise hematocrit above 52%, increasing blood viscosity and, theoretically, thrombotic risk. The FDA label for testosterone enanthate includes a warning about polycythemia [13]. Monitoring hematocrit every 3 to 6 months is standard practice in adolescents on ongoing testosterone therapy.

Non-Medical Use in Adolescents: The Performance Enhancement Context

Testosterone enanthate is the most commonly identified injectable anabolic-androgenic steroid in adolescent doping cases. The 2021 Monitoring the Future survey found that 1.6% of 12th-grade males reported using anabolic steroids in the past year, a figure that has remained relatively stable since 2015 [14].

Non-medical use by healthy adolescents produces all of the risks described above without any of the clinical benefits that justify prescription use. Growth plate closure, HPG axis suppression, and cardiovascular effects occur at the doses typically self-administered (200 mg to 500 mg per week, or 10 to 50 times a physiologic replacement dose).

The American Academy of Pediatrics (AAP) policy statement on performance-enhancing substances states unequivocally that anabolic steroid use by adolescents is medically contraindicated and ethically indefensible as a sports supplement.

The HealthRX clinical team has developed a staged risk-stratification framework for adolescents presenting with questions about testosterone. Stage 1 covers confirmed hypogonadism requiring replacement (low risk, appropriate use). Stage 2 covers CDGP candidates for short-course induction (low-to-moderate risk, guideline-supported). Stage 3 covers healthy adolescents seeking performance enhancement (high risk, no medical justification, requires counseling and referral). Each stage maps to distinct monitoring protocols and physician communication strategies, which the HealthRX medical team applies during evaluations.

Monitoring Protocols for Adolescents on Testosterone Enanthate

Prescribing testosterone enanthate to an adolescent without a structured monitoring plan is clinically inappropriate. The following reflects Endocrine Society 2023 guideline recommendations and standard pediatric endocrinology practice.

Required Baseline Studies

Before initiating therapy, every adolescent should have: serum total testosterone (morning, fasting), LH, FSH, SHBG, bone age X-ray (left hand/wrist), CBC, lipid panel, and a psychological readiness assessment. Karyotype is recommended if Klinefelter syndrome or a chromosomal disorder is suspected.

Ongoing Monitoring Schedule

• Serum testosterone: every 3 months for the first year, then every 6 months
• Bone age X-ray: every 6 months while growth plates remain open
• Hematocrit/hemoglobin: every 3 to 6 months
• Lipid panel: at 6 months, then annually
• LH and FSH: every 6 months (to assess HPG axis status)
• Height and weight: every visit

If bone age advancement exceeds chronological age advancement by more than 1 year over any 6-month period, the dose should be reduced or therapy paused, pending discussion with the patient and family.

What Happens After Stopping Testosterone Enanthate in Adolescents?

Recovery trajectory depends on duration of use, dose, and the underlying diagnosis.

For CDGP patients treated with a short 3 to 6 month course at 50 mg/month: HPG axis function resumes within weeks, spontaneous puberty proceeds normally in the majority of cases, and adult height is preserved.

For adolescents with primary hypogonadism, stopping testosterone replacement is generally not appropriate, as the underlying testicular failure is permanent. Dose tapering at the end of the growth period (bone age 17 to 18) transitions the patient to adult replacement protocols.

For healthy adolescents who used supraphysiologic doses illicitly, recovery depends on duration. After less than 6 months of use, full HPG axis recovery is expected in most patients within 6 to 12 months. After longer use, recovery is less predictable. A pediatric endocrinologist should supervise any discontinuation in this group, and referral for testosterone recovery support (clomiphene 25 mg daily or hCG 1,500 IU three times weekly) may be appropriate for prolonged suppression, though evidence for these protocols in adolescents specifically is extrapolated from adult data.

Key Takeaways for Clinicians and Parents

Testosterone enanthate has a legitimate and carefully circumscribed role in adolescent medicine. At physiologic doses, for confirmed diagnoses, under structured monitoring, it corrects hypogonadism, supports normal puberty, and improves quality of life without lasting harm to height or fertility in most patients.

The risks scale sharply with dose and duration. Supraphysiologic dosing, which defines virtually all non-medical use, carries a fundamentally different risk profile: irreversible growth plate changes, unpredictable HPG axis recovery, cardiovascular harm, and neurological effects on a brain that is not yet fully mature.

Any adolescent or parent asking about testosterone should be directed to a board-certified pediatric endocrinologist. Telehealth platforms that prescribe testosterone to patients under 18 without documented endocrine diagnosis and specialist oversight fall outside current standard of care. Per the Endocrine Society 2023 guideline, bone age X-ray is mandatory before any testosterone prescription in a growing adolescent, and the interval between X-rays must not exceed 6 months while growth remains active.